UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy

Leukemia, 2015-01, Vol.29 (1), p.11-19

2015

Volltextzugriff (PDF)

Safety and efficacy of dendritic cell (DC)-based cryoimmunotherapy (CryoIT) combined with checkpoint inhibition in a prospective non-randomized Phase I trial of metastatic castration resistant prostate cancer (mCRPC)

European urology open science (Online), 2020-07, Vol.19, p.e1844-e1845

2020

Volltextzugriff (PDF)

A randomized phase Ib/II study of the selective small molecule Axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma

Annals of oncology, 2019-10, Vol.30, p.v563

2019

Volltextzugriff (PDF)

1336TiP - A randomized phase Ib/II study of the selective small molecule Axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma

Annals of oncology, 2019-10, Vol.30, p.v563-v563

2019

Volltextzugriff (PDF)

LBA52 A randomized phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma

Annals of oncology, 2023-10, Vol.34, p.S1291-S1291

2023

Volltextzugriff (PDF)

Update on the randomised phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma

Annals of oncology, 2018-10, Vol.29, p.viii452-viii452

2018

Volltextzugriff (PDF)

1315O Key learnings from building: A precision cancer medicine implementation initiative for Norway

Annals of oncology, 2022-09, Vol.33, p.S1145

2022

Volltextzugriff (PDF)

503P The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway

Annals of oncology, 2022-09, Vol.33, p.S773

2022

Volltextzugriff (PDF)

Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia

Leukemia, 2014-08, Vol.28 (8), p.1738-1742

2014

Volltextzugriff (PDF)

Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia

Leukemia, 2012-05, Vol.26 (5), p.910-917

2012

Volltextzugriff (PDF)

Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris

The Lancet (British edition), 1991-01, Vol.337 (8735), p.193-196

1991

Volltextzugriff (PDF)

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

Leukemia, 2013-07, Vol.27 (7), p.1520-1526

2013

Volltextzugriff (PDF)

Review: genetic models of acute myeloid leukaemia

Oncogene, 2008-06, Vol.27 (27), p.3765-3779

2008

Volltextzugriff (PDF)

Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia

Oncogene, 2012-03, Vol.31 (12), p.1533-1545

2012

Volltextzugriff (PDF)

Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels

Leukemia, 2008-02, Vol.22 (2), p.287-293

2008

Volltextzugriff (PDF)

PB1723 DEVELOPING NOVEL COMBINED CSF1R/FLT3‐TARGETED THERAPY IN ACUTE MYELOID LEUKAEMIA

HemaSphere, 2019-06, Vol.3 (S1), p.792-n/a

2019

Volltextzugriff (PDF)

PS999 SINGLE CELL SIGNALING PHARMACODYNAMICS IN A PHASE 1B CLINICAL TRIAL OF THE AXL INHIBITOR BEMCENTINIB IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME

HemaSphere, 2019-06, Vol.3 (S1), p.449-450

2019

Volltextzugriff (PDF)

PS1176 PRIMARY RESULTS OF THE PHASE 4 BYOND STUDY OF BOSUTINIB FOR PRETREATED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA

HemaSphere, 2019-06, Vol.3 (S1), p.535-n/a

2019

Volltextzugriff (PDF)

PF259 THE COMBINATION OF BEMCENTINIB, A NOVEL, ORAL, SELECTIVE AXL‐INHIBITOR AND LOW‐DOSE CYTARABINE YIELDS DURABLE RESPONSES IN AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY

HemaSphere, 2019-06, Vol.3 (S1), p.81-n/a

2019

Volltextzugriff (PDF)

The genetic subtypes of cAMP-dependent protein kinase — Functionally different or redundant?

BBA - Molecular Cell Research, 1993-09, Vol.1178 (3), p.249-258

1993

Volltextzugriff (PDF)

Expression of Fcε-receptors by human acute myelogenous leukemia (AML) blasts: studies of high- and low- (CD23) affinity receptor expression and the effects of IgE-mediated receptor ligation on functional AML blast characteristics

Leukemia research, 2002-05, Vol.26 (5), p.515-521

2002

Volltextzugriff (PDF)

Antiapoptotic effect of heterozygously expressed mutant RI (Ala336-->Asp) subunit of cAMP kinase I in a rat leukemia cell line

The Journal of biological chemistry, 1993-04, Vol.268 (11), p.8332-8340

1993

Volltextzugriff (PDF)

P087 Clobetasol propionate in psoriasis — Monotherapy and in combinations

Journal of the European Academy of Dermatology and Venereology, 1997-09, Vol.9, p.S173-S174

1997

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Humans
(8)
Oncology
(8)
Biological And Medical Sciences
(7)
Leukemia
(7)
Hematology
(6)
Medical Sciences
(5)
Mutation
(5)
Acute Myeloid Leukemia
(4)
Adult
(4)
Aged
(4)
Animals
(4)
Biochemistry & Molecular Biology
(4)
Female
(4)
Hematologic And Hematopoietic Diseases
(4)
Leukemia, Myeloid, Acute - Genetics
(4)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(4)
Male
(4)
Middle Aged
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy

Safety and efficacy of dendritic cell (DC)-based cryoimmunotherapy (CryoIT) combined with checkpoint inhibition in a prospective non-randomized Phase I trial of metastatic castration resistant prostate cancer (mCRPC)

A randomized phase Ib/II study of the selective small molecule Axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma

1336TiP - A randomized phase Ib/II study of the selective small molecule Axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma

LBA52 A randomized phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma

Update on the randomised phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma

1315O Key learnings from building: A precision cancer medicine implementation initiative for Norway

503P The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway

Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia

Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia

Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

Review: genetic models of acute myeloid leukaemia

Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia

Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels

PB1723 DEVELOPING NOVEL COMBINED CSF1R/FLT3‐TARGETED THERAPY IN ACUTE MYELOID LEUKAEMIA

PS999 SINGLE CELL SIGNALING PHARMACODYNAMICS IN A PHASE 1B CLINICAL TRIAL OF THE AXL INHIBITOR BEMCENTINIB IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME

PS1176 PRIMARY RESULTS OF THE PHASE 4 BYOND STUDY OF BOSUTINIB FOR PRETREATED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA

PF259 THE COMBINATION OF BEMCENTINIB, A NOVEL, ORAL, SELECTIVE AXL‐INHIBITOR AND LOW‐DOSE CYTARABINE YIELDS DURABLE RESPONSES IN AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY

The genetic subtypes of cAMP-dependent protein kinase — Functionally different or redundant?

Expression of Fcε-receptors by human acute myelogenous leukemia (AML) blasts: studies of high- and low- (CD23) affinity receptor expression and the effects of IgE-mediated receptor ligation on functional AML blast characteristics

Antiapoptotic effect of heterozygously expressed mutant RI (Ala336-->Asp) subunit of cAMP kinase I in a rat leukemia cell line

P087 Clobetasol propionate in psoriasis — Monotherapy and in combinations

Suchergebnisse filtern